Have a feature idea you'd love to see implemented?
Let us know!
BNTC Benitec Biopharma Inc
Price (delayed)
$10.2
Market cap
$236.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.03
Enterprise value
$169.09M
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It
Highlights
The equity has soared by 188% YoY and by 36% from the previous quarter
The company's quick ratio has surged by 161% YoY and by 44% QoQ
BNTC's net income is up by 4.1% since the previous quarter but it is down by 2.1% year-on-year
The gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of BNTC
Market
Valuations
Earnings
Shares outstanding
23.22M
Market cap
$236.81M
Enterprise value
$169.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$21.16M
EBITDA
-$20.81M
Free cash flow
-$19.59M
Per share
Balance sheet
Liquidity
EPS
-$0.03
Free cash flow per share
-$1.84
Book value per share
$6.08
Revenue per share
$0
TBVPS
$6.46
Total assets
$68.77M
Total liabilities
$4.59M
Debt
$211,000
Equity
$64.18M
Working capital
$63.78M
Debt to equity
0
Current ratio
15.01
Quick ratio
14.92
Net debt/EBITDA
3.25
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.6%
Return on equity
-62.1%
Return on invested capital
N/A
Return on capital employed
-33%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BNTC stock price
How has the Benitec Biopharma stock price performed over time
Intraday
-4.32%
1 week
-1.92%
1 month
-8.03%
1 year
173.46%
YTD
215.79%
QTD
10.99%
Financial performance
How have Benitec Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.41M
Net income
-$20.86M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
The operating income has declined by 10% year-on-year
BNTC's net income is up by 4.1% since the previous quarter but it is down by 2.1% year-on-year
Growth
What is Benitec Biopharma's growth rate over time
Valuation
What is Benitec Biopharma stock price valuation
P/E
N/A
P/B
1.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 75% YoY and by 50% QoQ
The equity has soared by 188% YoY and by 36% from the previous quarter
BNTC's P/B is 46% below its 5-year quarterly average of 3.1 but 40% above its last 4 quarters average of 1.2
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Benitec Biopharma business performance
Benitec Biopharma's return on equity has surged by 73% YoY and by 33% QoQ
Benitec Biopharma's ROA has soared by 67% YoY and by 29% from the previous quarter
Dividends
What is BNTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BNTC.
Financial health
How did Benitec Biopharma financials performed over time
The company's quick ratio has surged by 161% YoY and by 44% QoQ
BNTC's current ratio has surged by 157% year-on-year and by 43% since the previous quarter
The debt is 100% less than the equity
The equity has soared by 188% YoY and by 36% from the previous quarter
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.